Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Haloperidol for Delirium in Adult Critically Ill Patients
NCT03628391 · Erasmus Medical Center · PHASE3 · terminated · last registry update 2022-05-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped because of futility of being able to reach a one-day difference between treatment groups in the primary outcome of DCFD in the intended sample size.” | – | Registry record, Erasmus Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-04-07Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Olanzapine + Haloperidol (NCT05803642)
- 2023-03-24Also stopped (withdrawn): Baylor College of Medicine, Pimavanserin (NCT04809116)
- 2023-01-19Phase 3 first posted: Alexandria University, Quatiapine + Haloperidol (NCT05690698)
- 2023-01-17Also stopped (terminated): Marubeni Pharmaceuticals (Suzhou) Co., Ltd., Lurasidone HCl + Placebo (NCT04383691)
- 2023-01-13Phase 3 first posted: Eurofarma Laboratorios S.A., FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo + etoricoxib 90 mg (Arcoxia®) +FDC placebo (NCT05683574)
- 2022-12-14Results posted on the registry: Adrianna Vlachos, MD, Trifluoperazine (NCT03966053)
- 2022-12-14Also stopped (terminated): Adrianna Vlachos, MD, Trifluoperazine (NCT03966053)
- 2022-12-02Results posted on the registry: Tonix Pharmaceuticals, Inc., TNX-102 SL + Placebo SL Tablet (NCT04508621)
- 2022-11-04Also stopped (terminated): The University of Hong Kong, Olanzapine + Haloperidol (NCT02380118)
- 2022-11-04Also stopped (terminated): The University of Hong Kong, Olanzapine oro-dispersible 5Mg Tab + Haloperidol 2Mg encapsulated Tab (NCT03246620)
- 2022-11-01Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-810 (18 mg) + SPN-810 (36 mg) (NCT02618408)
- 2022-10-27Also stopped (withdrawn): Sadat City University, ChlorproMAZINE 50 MG + Control (NCT05433402)
- 2022-09-27Phase 3 first posted: ACADIA Pharmaceuticals Inc., Pimavanserin (NCT05555615)
- 2022-09-01Results posted on the registry: M.D. Anderson Cancer Center, Chlorpromazine + Haloperidol (NCT03021486)
- 2022-08-31Phase 3 first posted: ACADIA Pharmaceuticals Inc., Pimavanserin + Placebo (NCT05523895)
- 2022-08-31Results posted on the registry: Baylor College of Medicine, Pimavanserin (NCT04188392)
- 2022-08-08Results posted on the registry: Tonix Pharmaceuticals, Inc., TNX-102 SL + Placebo SL Tablet (NCT04172831)
- 2022-07-01Also stopped (terminated): University of Witten/Herdecke, Loxapine (NCT02820519)
- 2022-06-24Phase 3 first posted: M.D. Anderson Cancer Center, Haloperidol + Chlorpromazine (NCT05431595)
- 2022-06-14Results posted on the registry: Joseph Dib, Haloperidol + Promethazine + Chlorpromazine + Haloperidol + Promethazine (NCT03639558)
- 2022-06-08Results posted on the registry: Cycle Pharmaceuticals Ltd., Haloperidol Tablets, Mylan Pharmaceuticals Inc. + Haloperidol Tablets, Cycle Pharmaceuticals Ltd (NCT04411940)
- 2022-06-08Results posted on the registry: Cycle Pharmaceuticals Ltd., Haloperidol Tablets, Mylan Pharmaceuticals Inc. + Haloperidol Tablets, Cycle Pharmaceuticals Ltd (NCT04411953)
- 2022-04-12Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Intranasal midazolam + Intramuscular loxapine (NCT05324852)
- 2022-04-05Results posted on the registry: ACADIA Pharmaceuticals Inc., Pimavanserin (NCT04000009)
- 2022-04-05Also stopped (terminated): ACADIA Pharmaceuticals Inc., Pimavanserin (NCT04000009)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision